Condition: Neuroendocrine Tumors · Sponsor: Peter MacCallum Cancer Centre, Australia
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
This description comes directly from the study's public registry record.
Grace Kong · 85595000 · NMResearch@petermac.org
Research Manager · 8559 6602
Always discuss trial participation with your own doctor first.
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05053854